ERBB2 and gastroesophageal junction adenocarcinoma: On 15 January 2021, the FDA approved T-DXd for adult patients with locally advanced or metastatic HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based therapy regimen [33].